Survival distribution was estimated by the Kaplan Meier method. Significant differences in probability of survival between the strata were evaluated by log rank test. A significant NSC 125973 level of 0. 05 was chosen to assess the statistical significance. Coxs multiple regression analysis was used to assess the role of polymorphisms as prognostic factors ad justed for those variables resulted significant at univar iate analysis. For statistical analysis, overall survival progression free survival were defined as the interval Inhibitors,Modulators,Libraries between the date of beginning of sorafenib treatment to death or last follow up visit, and to clinical progression or death or last follow up visit if not progressed.
The clinical variables analyzed were gender, age, ECOG Inhibitors,Modulators,Libraries PS, Child Pugh score, BCLC stage, median serum FP level, comorbidities, etiology, aspartate aminotransferase serum levels, alanine amino transferase serum levels, C reactive protein serum levels, HCV and HBV viral loads. Results Seventy eight patients were available for our analysis 72 males and 6 females. Median age was 69 years. All patients were in Child Pugh class A. Sorafenib dose reduction Inhibitors,Modulators,Libraries was applied in 16 patients with grade 3 and 4 toxicities. Inhibitors,Modulators,Libraries In the general popula tion median PFS was 4. 0 months, while median OS was 10. 7 months. The cut off point with the highest sensitivity and spe cificity for estimating pre treatment LDH serum levels as a function of treatment clinical activity was set after ROC curve analysis at 407 U/l both for PFS and OS. Fifty three patients showed pretreatment LDH serum levels below the cut off, while 25 were found above the chosen cut off.
Twenty six patients showed decreased LDH serum levels after treatment, while in 52 this value increased. At univariate analysis patients with LDH values below the cut off median PFS was 6. 7 months, whereas it was of 1. 9 months in patients above the cut off. Accordingly median OS was 13. 2 months and 4. 9 months in the two groups. In patients with decreased Inhibitors,Modulators,Libraries LDH values after treatment median PFS was 6. 8 months, and median OS was 21. 0 months, whereas PFS was 2. 9 months and OS was 8. 6 in patients with increased LDH levels. A statistical significant difference in term of PFS and OS was found between patients in B or C stage of BCLC classification. At multivariate analysis LDH serum levels pre treatment, the variation post treatment and BCLC stage emerged as independent prognostic factors predicting outcome in terms of PFS.
No statistically significant differences were found accord ing to other clinical characteristics analyzed. Toxicity profiles between patients groups are reported in Table 2. Discussion The introduction of antiangiogenic drugs in HCC treatment saw a wide shift in patients outcome, al though a good initial response is observed, frequently this selleck chemicals Pacritinib results in a subsequent loss of efficacy.